Precision cancer medicine: Concepts, current practice, and future developments
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 730 KB, PDF-dokument
Precision cancer medicine is a multidisciplinary team effort that requires involvement and commitment of many stakeholders including the society at large. Building on the success of significant advances in precision therapy for oncological patients over the last two decades, future developments will be significantly shaped by improvements in scalable molecular diagnostics in which increasingly complex multilayered datasets require transformation into clinically useful information guiding patient management at fast turnaround times. Adaptive profiling strategies involving tissue- and liquid-based testing that account for the immense plasticity of cancer during the patient's journey and also include early detection approaches are already finding their way into clinical routine and will become paramount. A second major driver is the development of smart clinical trials and trial concepts which, complemented by real-world evidence, rapidly broaden the spectrum of therapeutic options. Tight coordination with regulatory agencies and health technology assessment bodies is crucial in this context. Multicentric networks operating nationally and internationally are key in implementing precision oncology in clinical practice and support developing and improving the ecosystem and framework needed to turn invocation into benefits for patients. The review provides an overview of the diagnostic tools, innovative clinical studies, and collaborative efforts needed to realize precision cancer medicine.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Journal of Internal Medicine |
| Vol/bind | 294 |
| Udgave nummer | 4 |
| Sider (fra-til) | 455-481 |
| Antal sider | 27 |
| ISSN | 0954-6820 |
| DOI | |
| Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:
A.E. has received honoraria from Amgen, AstraZeneca, Bayer, Diaceutics, and Roche. AvD holds patents on DNA‐methylation based methods for classifying tumor species (EP16710700 and EP15158660) and is supported by an Illumina research grant. A.S. received honoria for consulting and advisory boards from: Agilent, Aignostics, Amgen, Astra Zeneca, Bayer, BMS, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Pfizer, Qlucore, Roche, Seagen, Takeda, Thermo Fisher. Grants: Bayer, BMS, Chugai, Incyte. C.A.‐P. Catherine Alix‐Panabières is one of the patent holders (US Patent Number 16,093,934) for detecting and/or characterizing CTCs. She received honoraria from Menarini. Funding: C.A.‐P. is supported by the ELBA project and has received funding from the European Union Horizon 2020 Research and Innovation program under the Marie Skłodowska‐Curie grant agreement No 765492, by the National Institute of Cancer (INCa, http://www.e‐cancer.fr ), SIRIC Montpellier Cancer Grant INCa_Inserm_DGOS_12553, the ERA‐NET TRANSCAN 2 JTC 2016 PROLIPSY, la Fondation ARC pour la Recherche sur le cancer, and les Fonds de dotation AFER pour la recherche médicale. P.O. has an advisory role for Alexion, Array, Bristol‐Myers Squibb, Celldex, CytomX, Genentech, Merck, Neon Therapeutics, Novartis, Pfizer, TRM Oncology, Evaxion, Immunetune, Servier, MyNeo, Phio. Grants to institution: Armo Biosciences, AstraZeneca/MedImmune, Bristol‐Myers Squibb, Celldex, CytomX, Genentech, Merck, Neon Therapeutics, Novartis, Pfizer. S.O. has a consulting or advisory role for: Bayer, Illumina, Roche; honoraria: Amgen, Eli Lilly, PharmaMar, Roche; research funding: AstraZeneca, Pfizer, PharmaMar, Roche; travel or accommodation expenses: Amgen, Eli Lilly, Illumina, PharmaMar, Roche. The remaining coauthors do not declare any conflicts of interest with respect to this work.
Publisher Copyright:
© 2023 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
ID: 371909463